BRINGING YOU INFORMATION.  PROVIDING YOU A PLATFORM.

 

 
THE PHARMA REVIEW (SEPTEMBER OCTOBER 2020)

When Moisture is Torture

Bry-Air

Introduction: Despite business disruptions due to the pandemic, India continues to position itself as a stable and low-cost pharmaceutical manufacturer across the globe. In current times as well, the heavily regulated markets such as the USA, UK, Australia, Germany, France, etc. continue to bank on Indian pharmaceutical products. For delivering consistent quality, the country has a robust network of 3,000 drug companies with around 10,500 manufacturing plants. Out of these, nearly 1400WHO-GMP approved plants, and many are US-FDA compliant with modern state-of-art technology.The strong infrastructure, and high-quality standards distinguish India as a consistent global pharmaceutical manufacturer.

 

Go to Content Index Page

PHARMA REVIEW - ARTICLES ARCHIVE ( COMPLETE LIST)

 

The above content is an abstract only. For the full Article please contact:
KONGPOSH Publications Pvt. Ltd.
ICS House, C-19, Commercial Complex, SDA, Opp. IIT Gate, New Delhi, India -110016
Tel.: 26855839, 9811195411
Email: kongposhpub@gmail.com, Website: http://www.kppub.com

 
 
 
 

Copyright KONGPOSH PUBLICATIONS Pvt. Ltd.